NewTimeSpace News: Sino Biopharmaceutical Limited (01177.HK) announced that its subsidiary Chia Tai Tianqing Pharmaceutical Group Co., Ltd. has entered into an exclusive strategic cooperation with GlaxoSmithKline (GSK). Chia Tai Tianqing will be responsible for the import, distribution, hospital access and promotion of bepirovirsen in Chinese Mainland.Bepirovirsen is a first-in-class antisense oligonucleotide (ASO) for the treatment of chronic hepatitis B (CHB) in adults. It has been included in both the Breakthrough Therapy Designation and Priority Review process. There are approximately 75 million hepatitis B virus-infected individuals in China.
NewTimeSpace News: Jiangsu Hengrui Pharmaceutical Co., Ltd. (01276.HK) announced that the Company and its subsidiaries have received Notices of Approval for Clinical Trials from the NMPA for five drugs, including HRS-6093 Tablets, SHR-9839 (sc) for Injection, SHR-1826 for Injection, Adebrelimab Injection, and SHR-8068 Injection. These drugs will be jointly evaluated in clinical trials for advanced malignant solid tumors with KRAS G12D mutation.Among them, HRS-6093 Tablets are a novel KRAS G12D inhibitor, with no similar products approved globally yet.
NewTimeSpace News: Jiangsu Hengrui Pharmaceutical Co., Ltd. (01276.HK) announced that it has received the Notice of Approval for Clinical Trials for HRS-3005 Tablets issued by the NMPA, approving clinical trials of the product for B-cell malignancies. HRS-3005 Tablets are an innovative anti-tumor drug independently developed by the Company. No similar drugs have been approved for marketing globally to date, with accumulated R&D investment of approximately RMB 26.2 million.
NewTimeSpace News: SSY Group Limited (02005.HK) announced that the Group has obtained drug production registration approvals from the National Medical Products Administration (NMPA) for three products. Among them, Fat-Soluble Vitamin Injection (Ⅰ) (10ml) is the first approved domestic enterprise, deemed to have passed the consistency evaluation, for intravenous nutritional supplementation in children and infants. Metformin Hydrochloride Tablets (0.5g and 0.25g) are used for the treatment of type 2 diabetes mellitus. Doxazosin Mesylate Extended-Release Tablets (4mg) are indicated for benign prostatic hyperplasia and hypertension.
NewTimeSpace News: Suzhou Raybow Biotech Co., Ltd. (06938.HK) announced that it has achieved the third key milestone in its R&D collaboration with Boehringer Ingelheim (BI) for developing innovative therapeutic solutions for liver diseases (including Metabolic Dysfunction-Associated Steatohepatitis, MASH). MASH is a severe and progressive fatty liver disease affecting over 200 million people worldwide.
NewTimeSpace News: Simcere Pharmaceutical Group Limited (02096.HK) announced that SIM0613 for Injection, a self-developed antibody-drug conjugate (ADC) targeting LRRC15, has obtained the Clinical Trial Approval Notice issued by the National Medical Products Administration (NMPA). A clinical trial for advanced solid tumors is planned to be launched. Previously, Simcere Zaiming, a subsidiary of the Group, has signed an exclusive license agreement with Ipsen, entitling it to receive a total payment of up to USD 1.06 billion.
NewTimeSpace News: SSY Group Limited (02005.HK) announced that the Group has obtained the drug production registration approval issued by the National Medical Products Administration (NMPA) for Diltiazem Hydrochloride for Injection (10mg). Classified as a Class 4 chemical drug, it is deemed to have passed the consistency evaluation. Meanwhile, the Group has also secured registration approval for Propranolol Hydrochloride Injection (specifications: 5ml:5mg and 2ml:2mg). As a Class 3 chemical drug, it is also recognised as passing the consistency evaluation.
NewTimeSpace News: CSPC Pharmaceutical Group Limited (01093.HK) announced that SYS6051, developed by the Group, has been approved by the National Medical Products Administration (NMPA) to initiate clinical trials in China. The product is a tissue factor (TF)-targeted antibody-drug conjugate (ADC) and was filed as a Class 1 therapeutic biological product. The approved indication is advanced solid tumors.
NewTimeSpace News, according to an announcement disclosed on the Singapore Exchange, Telix announced on April 13 that it has entered into a strategic collaboration with Regeneron to jointly develop and commercialize next-generation radiopharmaceutical therapies under a 50/50 cost and profit-sharing model.
NewTimeSpace News: Peijia Medical Limited (09996.HK) announced the successful completion of the first patient implant in the US FDA early feasibility study of the GeminiOne® Transcatheter Edge-to-Edge Repair (TEER) System.The procedure was performed by Professor Saibal Kar, Clinical Professor of Medicine at the David Geffen School of Medicine at the University of California, Los Angeles.
GEO enters its operational deployment phase in 2026, as financial institutions pivot their evaluation criteria from binary presence ("have or have not") to scientific efficacy and measurable impact. Youliancloud proposes four golden standards: systematic monitoring, citation-rate penetration through traffic flows, faithful restoration of official investment research logic, and constructing multi-dimensional closed-loop systems for sustainable long-term positioning.
NewTimeSpace: SSY Group Limited (02005.HK) announced that its calcium chloride has been approved by the National Medical Products Administration (NMPA) of China for registration as an active pharmaceutical ingredient (API) for use in marketed finished products.Calcium chloride is mainly indicated for the treatment of calcium deficiency, tetany and other conditions.
NewTimeSpace: MicroPort NeuroScientific Corporation (02172.HK) announced that its independently developed APOLLO Dream® Sirolimus Targeted Eluting Stent System has recently been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA).It is the world’s first balloon-expandable, rapid-exchange drug-eluting stent in the neurointerventional field to receive this designation.
NewTimeSpace: Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (02566.HK) announced that its independently developed JY47 Injection has obtained implicit approval for clinical trials from the National Medical Products Administration (NMPA) of China. The drug is intended for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis.
This guide advocates for a paradigm shift in financial digital asset evaluation via YouLianCloud GEOPlus. It introduces a three-tier framework: the Information Layer focuses on official recall rates for semantic accuracy; the Data Layer emphasizes structural compliance to boost source authority; and the Communication Layer targets multi-source citation frequency to build algorithmic consensus. This L3 standard ensures financial brands achieve high-weight, high-trust visibility in the generative AI search era.
On March 16, SmartMore Inc. officially filed for a Hong Kong IPO. Founded by Dr. Jia Jiaya and backed by the HKIC, the firm reported 2025 revenue of RMB 1.086 billion. Its proprietary IndustryGPT model now serves over 730 global clients, including Tesla and Zeiss. IPO proceeds will primarily fund R&D for industrial multi-modal models and accelerate international commercial expansion.
